Eupraxia Pharmaceuticals Inc.
TSX:EPRX.TOBiotechnology
+$0.22 today
- Market cap
- $595.76M
- Beta
- 1.48
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.74
Volume 0.16M
Average 0.05M
EPRX.TO Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Eupraxia Pharmaceuticals Inc.TSX: EPRX.TO
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q1 FY2026 selling, general & admin of $4.78M rose 108.0% year over year, behind the +115.0% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 43.1% from the prior quarter. Over 3 fiscal years it compounded at +43.3% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +56.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $4.78M-43.1% QoQ
- Last fiscal yearDec 2025
- $17.1M+56.6% YoY
- LTMMar 2026
- $17.9M+115.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +108.0% | -100.0% | -208.0 pp |
| 1 year | +56.6% | -100.0% | -156.6 pp |
| 3-year CAGR | +43.3% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
Mixed currencies · from the income statement
- Latest · FY2025
- 17.1M USD
- Year-over-year change
- +56.6%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.1M | +56.6% |
| FY2024 | 2024-12-31 | 10.92M | +48.2% |
| FY2023 | 2023-12-31 | 7.37M | — |
| FY2022 | 2022-12-31 | 5.81M | -29.2% |
| FY2021 | 2021-12-31 | 8.2M | — |
Selling, General & Admin vs competitors
How EPRX.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +115.0% is the highest of 8, against a peer median of +1.0%.
- Over three fiscal years its annual growth of +43.3% compares with a peer median of +5.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$122.93M CAD | +1.0% | -25.6% | 39.5% | |
| LTM Mar 2026 | $113.29M USD | -17.3% | -15.6% | 37.1% | |
| LTM Mar 2026 | CA$92.99M CAD | +36.2% | — | 33.9% | |
| LTM Mar 2026 | $84.46M USD | -22.8% | -10.9% | 32.3% | |
| LTM Mar 2026 | $53.08M USD | +34.4% | +31.8% | 103.7% | |
PRN.TOProfound Medical Corp. | LTM Mar 2026 | $30.43M USD | +14.7% | +22.1% | 162.2% |
| LTM Mar 2026 | $17.9M USD | +115.0% | +43.3% | — | |
| LTM Apr 2026 | CA$1.67M CAD | -34.6% | +45.7% | — | |
| Peer median (excluding EPRX.TO) | — | +1.0% | +5.6% | 38.3% | |
Competitors are the stored peer set for EPRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · USD | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 111.53K | 193.27K | 158.05K | 163.47K | 241.88K |
| Gross Profit | (111.53K) | (193.27K) | (158.05K) | (163.47K) | (241.88K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 10.17M | 17.58M | 21M | 15.17M | 21.51M |
| Selling, General & Admin | 8.2M | 5.81M | 7.37M | 10.92M | 17.1M |
| Operating Expenses | 18.38M | 23.38M | 28.37M | 25.54M | 38.86M |
| Depreciation & Amortization | 111.53K | 193.27K | 158.05K | 163.47K | 241.88K |
| EBITDA | (21.96M) | (22.14M) | (28.16M) | (23.43M) | (38.86M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (18.47M) | (23.58M) | (27.78M) | (25.71M) | (39.11M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 65.73K | 569.32K | 876.96K | 1.1M | 1.44M |
| Interest Expense | 1.3M | 1.59M | 1.19M | 913.1K | 0 |
| Other Income / Expenses | (4.9M) | (341.09K) | (1.08M) | 1.2M | (155.19K) |
| Income Before Tax | (23.37M) | (23.92M) | (28.93M) | (24.51M) | (39.26M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | (67.51K) | 1.72K | 19.42K |
| Net Income | (22.99M) | (23.26M) | (28.15M) | (24.28M) | (39.25M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.61) | (1.21) | (1.19) | (0.72) | (1.05) |
| EPS (Diluted) | (1.61) | (1.21) | (1.19) | (0.72) | (1.05) |
| Weighted Avg Shares | 14.24M | 19.29M | 24.15M | 33.93M | 39.96M |
| Weighted Avg Shares (Diluted) | 14.24M | 19.29M | 24.15M | 33.93M | 39.96M |
Eupraxia Pharmaceuticals Inc.
TSX:EPRX.TO
Intrinsic Alpha fair value
Locked
Current Price
$8.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.